Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia

British Medical Journal

Volumn 314, Issue 7089, 1997, Pages 1238-1244

  Gøtzsche, Peter C ^a   Johansen, Helle Krogh ^a  

^a University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE;

ARTICLE; BLOOD CULTURE; CANCER; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGITIS; HUMAN; LUNG MYCOSIS; MAJOR CLINICAL STUDY; META ANALYSIS; MORBIDITY; MORTALITY; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL; PROPHYLAXIS;

EID: 8244226648     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.314.7089.1238     Document Type: Article

References (59)

1. Inagaki J, Rodriguez V, Bodey G. Causes of death in cancer patients. Cancer 1974;33:568-73.
2. Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ. Causes of initial remission induction failure in acute myelogenous leukemia. Blood 1982;60:309-15.
3. Walsh TJ, Lee J, Lecciones J, Rubin M, Butler K, Francis P, et al. Empiric therapy with amphotericin B in febrile granulocytopenic patients. Rev Infect Dis 1991;13:496-503.
4. Verfaillie C, Weisdorf D, Haake R, Hostetter M, Ramsay N, McGlave P. Candida infections in bone marrow transplant recipients. Bone Marrow Transplant 1991;8:177-84.
5. Meyers JD. Fungal infections in bone marrow transplant patients. Semin Ontol 1990;17:10-3.
6. Walsh TJ. Role of surveillance cultures in prevention and treatment of fungal infections. Natl Cancer Inst Monogr 1990;9:43-5.
7. Stein RS, Greer JP, Ferrin W, Lenox R, Baer MR, Flexner JM. Clinical experience with amphotericin B in acute myelogenous leukemia. South Med J 1986;79:863-70.
8. Berlin JA, Begg CB, Louis TA. An assessment of publication bias using a sample of published clinical trials. J Am Stat Assoc 1989;84:381-92.
9. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias, dimension of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
10. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986;7:177-88.
11. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71.
12. Lau J, Chalmers TC. Meta-analyst 0.975 program. Boston: 1994.
13. Ezdinli EZ, O'Sullivan DD, Wasser LP, Kim U, Stutzman L. Oral amphotericin for candidiasis in patients with hematologic neoplasms. An autopsy study. JAMA 1979;242:258-60.
14. Suda T, Omine M, Tsuchiya J, Maekawa T, Muto Y, Mizoguchi H, et al. A cooperative study of prophylaxis against fungal infection in patients with hematological diseases: prophylactic effect of oral amphotericin B. Rinsho Ketsueki 1980;21:195-9. [In Japanese.]
15. Perfect JR, Klotman ME, Gilbert CC, Crawford DD, Rosner GL, Wright KA, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992;165:891-7.
16. Riley DK, Pavia AT, Beatty PG, Petersen FB, Spruance JL, Stokes R, et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994;97:509-14.
17. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-11.
18. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:668-72.
19. Tollemar J, Hockerstedt K, Ericzon BG, Sundberg B, Ringden O. Fungal prophylaxis with AmBisome in liver and bone marrow transplant recipients: results of two randomized double-blind studies. Transplant Prof 1994;26:1833.
20. Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Sparrelid E, et al. Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients. Transplant Proc 1993;25(1 pt 2):1495-7.
21. Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Tyden G. Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993;12:577-82.
22. Goldstone AH, O'Driscoll A. Early AmBisome in febrile neutropenia in patients with haematological disorders. Bone Marrow Transplant 1994;14(suppl 5):S15-7.
23. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
24. Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993;118:495-503.
25. Yamac K, Senol E, Haznedar R. Prophylactic use of fluconazole in neutropenic cancer patients. Postgrad Med J 1995;71:284-6.
26. Slavin MA, Osborne B, Adams R, Levenstein M, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-52.
27. Fukuda M, Hirashima K, Kurane R, Abe T, Sampi K, Tominaga K, et al. Empiric therapy with fluconazole in granulocytopenic patients with carcinoma or leukemia. Jpn J Antibiot 1994;47:1065-70. [In Japanese.]
28. Acuna G, Winston DJ, Young LS. Ketoconazole prophylaxis of fungal infections in the granulocytopenic patient: a double-blind, randomized controlled trial. Paper presented at 22nd interscience conference on antimicrobial agents and chemotherapy, American Society for Microbiology, 1981. Abstract 852.
29. Siegel M, Murphy M, Counts GW, Meyers JD. Prophylactic ketoconazole for the prevention of fungal infection in bone marrow transplant patients. Paper presented at 23rd interscience conference on antimicrobial agents and chemotherapy, American Society for Microbiology, 1982. Abstract 166.
30. Palmblad J, Lönnqvist B, Carlsson B, Grimfors G, Järnmark M, Lerner R, et al. Oral ketoconazole prophylaxis for Candida infections during induction therapy for acute leukaemia in adults: more bacteraemias. J Intern Med 1992;231:363-70.
31. Brincker H. Prevention of mycosis in granulocytopenic patients with prophylactic ketoconazole treatment. Mykosen 1983;26:242-7.
32. Hughes WT, Bartley DL, Patterson GG, Tufenkeji H. Ketoconazole and candidiasis: a controlled study. J Infect Dis 1983;147:1060-3.
33. Estey E, Maksymiuk A, Smith T, Fainstein V, Keating M, McCredie KB, et al. Infection prophylaxis in acute leukemia. Comparative effectiveness of sulfamethoxazole and trimethoprim, ketoconazole, and a combination of the two. Arch Intern Med 1984;144:1562-8.
34. Hansen RM, Reinerio N, Sohnle PG, Abrams RA, Ritch PS, Libnoch JA, et al. Ketoconazole in the prevention of candidiasis in patients with cancer. A prospective, randomized, controlled, double-blind study. Arch Intern Med 1987;147:710-2.
35. Benhamou E, Hartmann O, Nogues C, Maraninchi D, Valteau D, Lemerle J. Does ketoconazole prevent fungal infection in children treated with high dose chemotherapy and bone marrow transplantation? Results of a randomized placebo-controlled trial. Bone Marrow Transplant 1991;7:127-31.
36. Brincker H. Prophylactic treatment with miconazole in patients highly predisposed to fungal infection. A placebo-controlled double-blind study. Acta Med Scand 1978;204:123-8.
37. Wingard JR, Vaughan WP, Braine HG, Merz WG, Saral R. Prevention of fungal sepsis in patients with prolonged neutropenia: A randomized, double-blind, placebo-controlled trial of intravenous miconazole. Am J Med 1987;83:1103-10.
38. Prentice AG, Bradford GR. Prophylaxis of fungal infections with itraconazole during remission-induction therapy. Mycoses 1989;32(suppl 1):96-102.
39. Vreugdenhil G, Van Dijke BJ, Donnelly JP, Novakova IRO, Raemaekers JMM, Hoogkamp-Korstanje MAA, et al. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymphoma 1993;11:353-8.
40. Caselli D, Arico M, Michelone G, Cavanna C, Nespoli L, Burgio GR. Antifungal chemoprophylaxis in cancer children: a prospective randomized controlled study. Microbiologica 1990;13:347-51.
41. Schaison G, Baruchel A, Arlet G. Prevention of Gram-positive and Candida albicans infections using teicoplanin and fluconazole: a randomized study in neutropenic children. Br J Haematol 1990;76(suppl 2):24-6.
42. Bodey GP, Samonis G, Rolston K. Prophylaxis of candidiasis in cancer patients. Semin Oncol 1990;17(suppl 6):24-8.
43. Goodman JL, Greenfield R, Buell D. Prophylactic fluconazole and marrow transplantation. N Engl J Med 1992;327:645.
44. Slavin M, Bowden R, Osborne B, Adams R, Levenstein M, Feldman A, et al. Fluconazole prophylaxis in marrow transplant recipients: a randomized placebo controlled double blind study. Paper presented at 32nd interscience conference on antimicrobial agents and chemotherapy, American Society for Microbiology, 1992. Abstract 623.
45. Pocock SJ. Size of cancel clinical trials and stopping rules. Br J Cancer 1978;38:757-66.
46. Buyse M. Interim analyses, stopping rules and data monitoring in clinical trials in Europe. Stat Med 1993;12:509-20.
47. Riley D, Beatty P, Pavia A, Evans TG. Prophylactic use of low-dose amphotericin B (AMB) in bone marrow transplant (BMT) patients. Paper presented at 32nd interscience conference on antimicrobial agents and chemotherapy, American Society for Microbiology, 1992. Abstract 620.
48. Green SJ, Fleming TR, Emerson S. Effects of overviews of early stopping rules for clinical trials. Stat Med 1987;6:361-7.
49. Hughes MD, Freedman LS, Pocock SJ. The impact of stopping rules on heterogeneity of results in overviews of clinical trials. Biometrics 1992;48:41-53.
50. Simes RJ, Stern J, Ghersi D. The importance of prospectively registering trials: evidence of publication bias from a cohort study of research protocols. 3rd Annual Cochrane colloquium, Oslo, 4-8 October 1995.
51. Simes RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol 1986;4:1529-41.
52. Huston P, Moher D. Pharmaceutical company trials and the integrity of medical research. Lancet 1996;347:1628.
53. Chalmers I. Underreporting research is scientific misconduct. JAMA 1990;263:1405-8.
54. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-33.
55. Working Party of the British Society for Antimicrobial Chemotherapy. Antifungal drug susceptibility testing. J Antimicrobial Chermother 1995;36:899-909.
56. Fraser IS, Denning DW. Empiric amphotericin B therapy: the need for a reappraisal. Blood Rev 1993;7:208-14.
57. Guiot HFL, Fibbe WE, van't Wout JW. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 1994;18:525-32.
58. Walsh TJ, Hiemenz J, Pizzo PA. Editorial response: evolving risk factors for invasive fungal infections - all neutropenic patients are not the same. Clin Infect Dis 1994;18:793-8.
59. Gøtzsche PG, Johansen HK. Antifungal prophylactic or empiric therapy vs placebo or no treatment in cancer patients with neutropenia. In: Garner P, Gelband H, Olliaro P, Salinas R, eds. Infectious diseases module of the Cochrane database of systemic reviews. The Cochrane library. Issue 2. Oxford: Update Software, 1997.